Human IgM monoclonal antibodies block HIV-transmission to immune cells in cervico-vaginal tissues and across polarized epithelial cells in vitro

Claudia Devito2,3, Rada Ellegård1, Tina Falkeborn1, Lennart Svensson1, Mats Ohlin4, Marie Larsson1, Kristina Broliden5 & Jorma Hinkula1

The importance of natural IgM antibodies in protection against infections is still emerging and these antibodies have a potential role in the maintenance of homeostasis through clearance of apoptotic bodies, complement-dependent mechanisms, inflammation and exclusion of misfolded proteins. Natural IgM act as a first line of defence against unknown hazardous factors and are present in most vertebrates. We investigated the functional capacity of anti-HIV-1 IgM monoclonal antibodies, from a combinatorial Fab library derived from healthy individuals, and evaluated their protective role in inhibiting HIV-1 in vitro when passing across the human mucosal epithelial barrier. Primary HIV-1 isolates were efficiently transmitted over the tight polarized epithelial cells when added to their apical surface. Efficient inhibition of HIV-1 transmission was achieved when anti-HIV-1 IgM monoclonal antibodies were added to the basolateral side of the cells. Two of these human IgM MoAbs had the ability to neutralize HIV and reduced infection of dendritic cells in primary cervico-vaginal tissue biopsies in vitro. This indicates a potential role of natural IgM antibodies in the reduction of HIV-1 transmission in mucosal tissues and improve our understanding of how natural IgM antibodies against a neutralizing epitope could interfere with viral transmission.

The establishment of HIV infection in the mucosa during sexual transmission is dependent on the virus ability of the virus to overcome layers of innate barriers/responses and find HIV target cells where the infection can be initiated. One important component of the innate responses is natural IgM (nIgM) antibodies. Our understanding of the role of these antibodies in the protection against infections is emerging; they function as the first line of defence in neutralizing invading pathogens, and they facilitate T-cell recognition, B-cell isotype switching, and the transport of antigens to lymphoid tissue1. Moreover, nIgM participate in tissue homeostasis by regulating inflammatory processes and autoimmune diseases2. IgM is generated at very early stages in B-cell ontogeny and is produced and secreted without antigen stimulation. Its pentameric structure allows the binding of multiple antigenic sites in both the systemic and mucosal compartments3–5. The circulating nIgM is polyreactive, whereas other immune IgM clones have specific antigen binding affinities6–8.

The main activity of nIgM is to facilitate the complement pathway, and there are enormous property variations among the IgM antibodies even if they have the same binding specificity. Mucosal tissue-associated B-lymphocytes produce IgA9, but they also produce IgM and IgG, and most of them produce the J chain polypeptide10. IgM antibodies bind to two receptors known as FcαR and polymeric Ig receptor11,12. The latter mediates transport through the mucosal epithelium of secretory IgM (S-IgM). Consequently, the antibodies present in

1Linköping University, Department of Clinical and Experimental Medicine, Division of Molecular Virology, 58185, Linköping, Sweden. 2Department of Virology, Swedish Institute for Infectious Disease Control, 17157, Solna, Sweden. 3HD Department of Clinical Virology, Stockholm, Sweden. 4Department of Immunotechnology, Lund University, Lund, Sweden. 5Department of Medicine Solna, Unit of Infectious Diseases B2:00, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet, 171 76, Stockholm, Sweden. Correspondence and requests for materials should be addressed to J.H. (email: Jorma.Hinkula@liu.se)

Received: 2 November 2017
Accepted: 19 June 2018
Published online: 05 July 2018
mucosal secretions can bind directly to external proteins on the viral surface, preventing attachment to the epithelium, or interact with and destroy the virus within the epithelial cell. It has been shown that HIV-1 can penetrate a tight epithelial cell barrier, IgA and IgM from colostrum and cervico-vaginal fluids from HIV-1-positive women neutralize HIV-1 transport across mucosal surfaces. Several human IgM-derived monoclonal antibodies (MoAbs) obtained from the blood, lymph nodes, and spleens of healthy donors showed high-avidity binding to gp120 derived from HIV isolates from different clades. These monoclonal antibodies selected from a large phage-displayed naive human antibody library did not neutralize CCR5 primary isolates, although weak neutralization was detected against all CXCR4 isolates. In HIV infection, antibodies against conserved epitopes need to develop early to allow the early humoral recognition of a broad HIV strain repertoire. However, most antibodies that react with gp120 bind to its variable regions and unfortunately only rarely to the conserved HIV epitopes, which display poor immunogenicity. The third variable loop region is one of the earliest identified regions containing neutralizing B cell epitopes and several studies have shown that the "tip" of the V3-region in the HIV-1 outer envelope of HIV-1 gp120 is relatively conserved. For that reason, we in a previous study, select B cells with natural production of IgM MoAbs recognizing the HIV-1 V3 region from HIV negative healthy individuals. The selected B cells were turned into immortalized cell lines. Interestingly, several anti-V3 IgM clones were detected, with the epitope recognition of the amino acid sequence 294–323, which contain the most conserved amino acids G-P-G V3-tip sequence in the HIV V3 region. They differed in avidity index, and in the size of the epitopes mapped. Moreover, a typical and highly relevant property with IgM antibodies is their relatively weak epitope-binding affinity, but their multi-valency still develop a fair avidity or "stickiness" against a target protein such as gp120. This property makes IgM molecules interesting to study, but hard to investigate in their detailed fine-epitope-specificity. This HIV-1 envelope protein surfaces containing gp120/gp41 have been used as a target in experimental vaccine protocols. Antibodies against the CD4-binding domain (CD4BD) of gp120 are produced in small amounts in the pool of neutralizing antibodies in infected individuals, whereas others do not have any neutralizing activity at all even after CD4BD binding. It has been postulated that the failure to induce broad neutralizing antibodies ensues from differences in the molecular structures of monomeric and native gp120. However, oligomeric gp120 also fails to produce broad neutralizing antibodies. Nevertheless, antibodies against HIV gp120 amino acid residues 421–433 that are present before viral exposure have been shown to neutralize different HIV subtypes. The aim with this study was to establish if the naturally occurring IgM MoAbs we previously developed had antiviral efficacy against primary HIV-1 isolates so the ability of four HIV-1 gp120-binding human monoclonal antibodies derived from healthy individuals to block HIV-1 was analysed. We also determined whether the viruses remained infectious during transport within human cervical mcosa biopsies from healthy donors and the human intestinal epithelial cell line. The formation of Ag-IgM complexes could be one of the mechanisms responsible for the enhancement of humoral immune responses and could be a key component for prophylactic mucosal HIV intervention strategies.

Results
Transcytosis of IgM antibodies and HIV-1 across the polarized epithelial cell membrane. The properties of the propagated human IgM antibodies were first analysed by their transcytosis abilities. A Transwell model system was used to measure the epithelial transmembrane transport of the IgM monoclonal Abs using human Caco-2-pIgR+ cells, which are known to facilitate HIV-1 virus transcytosis in vitro. The kinetics of IgM transcytosis from the basolateral medium to the apical side of the polarized epithelial Caco-2-pIgR+ cells was assessed and at 24 h the IgM levels reached 1283 ng/ml (median 1284 ng/ml with range 1190–1362) (Fig. 1). Caco-2 cells without the pIgR expression did not allow transfer of IgM from the basolateral to the apical side of the Transwell cultures (data not shown). We further measured the transport capacity of HIV-1, primary isolates from clade B, and an HIV-1 Lai/IIIB laboratory strain. All HIV-1 isolates penetrated the Caco-2-pIgR+ cell line and was transported to the basolateral side and HIV-1 p24 antigen became detectable within 1 hour post-challenge at the basolateral side of the Transwell chamber system (Fig. 2A). The transcytosed viral particles in the basolateral medium represented an infectious virus because it gave rise to infection when co-cultured either with Jurkat T cells or human activated PBMCs (Fig. 2B). Because seminal plasma and cervical secretion are known to contain both viral particles and infected cells, we assessed the transcytosis efficacy when infected PBMCs were present at the apical side together with cell-free HIV-1. The addition of the HIV infected PBMCs enhanced the transcytosis for two of the HIV isolates namely Lai/IIIB and 6272.

Inhibition of transcytosis of infectious HIV-1 by human anti-HIV-1 env IgM monoclonal antibodies. We assessed the ability of the human anti-HIV IgM MoAbs MO101, MO97, and MO99 to inhibit transcytosis of a syncytium inducing HIV-1 clade B primary isolate 6794 and HIV-1 Lai/IIIB. Supernatant from the basolateral side of the Transwell chamber was collected 24 hours after exposure to virus and monolayer of epithelial cells. The epithelial cells in the Transwell chamber were washed, and the presence of infectious virus in the cells was determined using activated human PBMC as target cells. The MoAbs MO101 and MO99 significantly blocked the transcytosis at the basolateral side (91% and 89% p24 antigen reduction, respectively, p < 0.01) and within the cells (69% and 74% p24 antigen reduction, respectively, p < 0.01) as compared to HIV-1 with no antibody (Fig. 3A,B). The MoAb MO97 was less efficient in inhibiting HIV transcytosis (47% p24 antigen reduction, p = 0.15 n.s) compared to HIV-1 with no antibody present (Fig. 3B). Moreover, we observed no viral inhibition at any side of the polarized epithelium or in the cells when the MO101 was added in the presence of soluble rgp160, which neutralizes the MoAbs (Fig. 3A,B). The non-HIV neutralizing control MoAb MO6 did not significantly inhibit the transcytosis (Fig. 3A). A summary of the basolateral HIV-1-inhibiting properties of the HIV-1 envelope-specific MoAbs and negative controls are shown in Table 1. Inhibition of HIV-1 was not
detected in our control experiments using human anti-Digoxin specific control MoAbs MO6 either alone or in combination with 10 µg of rgp160 (Table 1).

**Inhibition of HIV-1 by human IgM monoclonal antibodies against HIV-1 envelope in human target cells in vitro.** When the MoAbs were tested against free HIV-1 virus with human T cell line Jurkat T cells three MoAbs were shown capable of neutralizing two out of three HIV-1 isolates (Fig. 4A–C).

**Inhibition of HIV-1 by human IgM monoclonal antibodies against HIV-1 envelope in human cervical mucosa biopsies and transfer and infection to mucosal Dendritic cells.** To further investigate the HIV-1-inhibiting properties of the IgM MoAbs we tested their capacity to block HIV replication in primary mucosal cervical tissues. The two anti-HIV MoAbs MO99 and MO96 reduced the amount of RT-activity by 70% (range 62–89) respectively 46% (range 38–62%) in ectocervical tissue explants, whereas no inhibition was observed with the MoAbs MO97 and MO101 or with control antibodies (Fig. 5A). In endocervical tissue explants, only MoAb MO99 succeeded in reducing the RT-activity, (28%, range 26–34%) (Fig. 5B), compared to tissues without antibody. To confirm the reduced HIV-1 RT in the supernatant from the cervical tissue explants exposed to MoAbs MO99, MO96, MO97, and MO101 we assessed the HIV-1 infection of emigrating cervical DCs by staining for HIV-1 p24. The MoAb MO99 reduced the percentage of HIV infected emigrating DCs from both endo and ectocervix, with significant reduction for the endocervical DCs (Fig. 6A,B).

**Discussion**

It is well known that the presence of early neutralizing antibodies during an infection can protect against lethal disease. IgM is the first immunoglobulin produced during a primary infection and can be transported through polarized mucosal tissues, thus providing a first layer of protection against invading pathogens. In some instances, it has been shown that IgM to have low affinity but high avidity with a broad antigen recognition capacity due to its multiple epitope-binding properties. Furthermore, IgM can interfere or inhibit bacterial and viral attachment and also viral infection of cells and tissues. Interestingly, even non-neutralizing IgM and IgG show viral infection-reducing properties and this has been reported for Marburg and Ebolavirus. For this reason, we evaluated whether anti-HIV IgM monoclonal antibodies were capable of inhibiting HIV-1 transcytosis through a polarized epithelial cell barrier *in vitro*. We demonstrated, in an intestinal epithelial cell line expressing plgR, that the antibodies were transported from the basolateral side to the apical surface. The plgR expressing epithelial cells also allowed the transport of infectious HIV-1 from the apical to the basolateral side of the polarized epithelium. We also showed that two human IgM monoclonal antibodies, MO96 and MO101, directed against the V3 loop region of HIV-1 gp120 inhibited HIV-1 transcytosis across the epithelial cell layer. This inhibition was observed when using an HIV-1 primary isolate of the SI phenotype and with a laboratory-adapted HIV-1 isolate. However, when the epithelial cells were challenged with the HIV-1 primary isolate of the NSI phenotype, no inhibition of the transcytosis was observed. This indicates that IgM epitope recognition of the transcytosed HIV-isolates is important and that the V3 region may be better exposed on the SI strains than on the NSI isolates. Primary isolates may have a more closed exposure of the outer envelope epitopes than T-cell line adapted HIV isolates. It was also possible to reduce the antiviral activity of MoAbs transcytosis by blocking with V3 peptides or rgp160 protein representing SI isolates, thus indicating the need for epitope specificity of the antibodies.
Interestingly, the monoclonal IgM antibodies with HIV-1 envelope specificity had some \textit{ex vivo} efficacy in reducing HIV-1 replication and intracellular entry into antigen-presenting cells, i.e. dendritic cells (DCs), in primary human cervical tissue samples. There was some degree of variability between the IgM MoAbs in their capacity to inhibit HIV-1 replication in ectocervical and endocervical tissues. The differences in their efficacy are not yet clear and it is important to note that the IgM concentrations used were not very high and spanned from 5 to 9 µg/mL. Another factor that may play a significant role is the difference in the IgM avidity against the HIV-1 envelope epitopes, as well as the gp120-V3 epitope specificities between the MoAbs previously described\cite{20}. Furthermore, a variation in the numbers and activation stages of the HIV-1-susceptible cells in the cervical tissue biopsies is also to consider. However, even with these assay limitations, an interesting result concerning the numbers of HIV-1 p24-positive DCs detected in the endo- and ecto-cervical biopsy tissues was observed in the presence of some of the IgM MoAbs. Depending on whether the tissue was collected from the endo- or ectocervix,
one or two of the IgM antibodies showed a reducing effect on the number of p24-positive DCs. This promising data obtained from the primary cervical tissues further indicate IgM anti-HIV-inhibiting properties.

Secretory IgA and IgM antibodies can be efficiently transcytosed and may function as the first specific barrier against infection 19,27,44. However, polymeric IgA is more efficiently transcytosed than polymeric IgM 44,45.

Virus-neutralizing antibodies in mucosal surfaces, such as interactions between IgA and influenza or Sendai viral

![Graph](image1)

**Figure 3.** Neutralization of infectious cell-free HIV-1 with human IgM monoclonal antibodies and controls. The *in vitro* neutralizing Human anti-HIV-1 IgM MO101, MO97, and MO99, MO96 and the control non-neutralizing MO86 and MO6 with three HIV-1 isolates at equal virus concentrations (25 TCID50) (A) with HIV-1 IIIB in (B) with HIV-1 6794 isolate and in (C) with HIV-1 6727 isolate. The 50% inhibited HIV-1 p24 detection is indicated with the dotted line.

| HIV-1 gp120 V3 specific | Time (h) | ELISA Rgp160 binding (OD)** | Inhibition of HIV-1 transcytosis | HIV-1 IIIB (SI)** | HIV-1 6794 (SI) | HIV-1 6727 (NSI) |
|-------------------------|---------|-----------------------------|----------------------------------|------------------|----------------|-----------------|
| MO96                    | 0       | 0.010/0.008                 |                                 | 87%/94%          | 90%/70%        | 25%/31%         |
|                         | 14      | 0.140/0.111                 |                                 | 90%/70%          | 25%/31%        | 87%/94%         |
|                         | 24      | 0.652/0.596                 |                                 | 91%/60%          | 25%/31%        | 87%/94%         |
| MO97                    | 0       | 0.009/0.010                 |                                 | 23%/13%          | 38%/0%         | 1%/-5%          |
|                         | 14      | 0.151/0.148                 |                                 | 28%/10%          | 1%/-5%         | 23%/13%         |
|                         | 24      | 0.497/0.483                 |                                 | 28%/10%          | 1%/-5%         | 23%/13%         |
| MO99                    | 0       | 0.011/0.012                 |                                 | 83%/79%          | 68%/70%        | 41%/36%         |
|                         | 14      | 0.201/0.209                 |                                 | 83%/79%          | 68%/70%        | 41%/36%         |
|                         | 24      | 0.599/0.604                 |                                 | 83%/79%          | 68%/70%        | 41%/36%         |
| MO101                   | 0       | 0.014/0.011                 |                                 | 88%/93%          | 91%/77%        | 5%/15%          |
|                         | 14      | 0.166/0.144                 |                                 | 91%/77%          | 90%/70%        | 5%/15%          |
|                         | 24      | 0.552/0.505                 |                                 | 91%/77%          | 90%/70%        | 5%/15%          |
| MO86                    | 0       | 0.007/0.009                 |                                 | 35%/36%          | 3%/4%          | 10%/13%         |
|                         | 14      | 0.103/0.098                 |                                 | 35%/36%          | 3%/4%          | 10%/13%         |
|                         | 24      | 0.393/0.402                 |                                 | 35%/36%          | 3%/4%          | 11%/13%         |
| Control IgM naked monoclonal antibody | 0       | 0.016/0.009                 |                                 | 44%/0%           | 11%/2%         | 18%/22%         |
|                         | 14      | 0.020/0.011                 |                                 | 34%/0%           | 11%/2%         | 18%/22%         |
|                         | 24      | 0.028/0.014                 |                                 | 34%/0%           | 11%/2%         | 18%/22%         |
| Medium                  | 0       | 0.014/0.010                 |                                 | 0%/0%            | 1%/0%          | 0%/0%           |
|                         | 14      | 0.020/0.012                 |                                 | 0%/0%            | 1%/0%          | 0%/0%           |
|                         | 24      | 0.018/0.012                 |                                 | 0%/0%            | 1%/0%          | 0%/0%           |

Table 1. Kinetics of IgM Mab-binding to recombinant gp160 and inhibition of HIV-1 transcytosis across Caco-2-IgR+ cells. *Apical transwell culture medium collected and tested for anti-gp160 IgM binding activity at 0–24 hours by ELISA. **Inhibition of HIV-1 p24 gag antigen in the basolateral transwell culture medium in the presence of anti-gp120 V3 Mabs compared with wells with control IgM or without antibodies.
envelope proteins and intracellular neutralization of influenza virus have been previously reported\textsuperscript{15,44}. In this study, we investigated whether the neutralization of HIV occurred at the intracellular or at the apical surface of the cell line. We could see the intracellular reduction of the p24 content with the addition of HIV-1-neutralizing MoAbs, which is accordance with Bomsel et al.\textsuperscript{16}. At best, approximately $6 \times 10^{11}$ IgM molecules in a 24 hour period could be transferred to the apical side of the cell line (data not shown). In the plgR-transfected cells, these values were $2.5 \times 10^{11}$ monoclonal IgM molecules per 20 hours. If each Ig-molecule has the capacity to neutralize one free HIV particle and if this epitope is available at the HIV-exposed mucosal surface, a high amount of neutralizing HIV-1-specific antibodies could be transported. Thus, as long as the antibodies can efficiently recognize the invading virus, this should be an opportunity for the immune defence to deliver a specific, sterilizing immunity. The effect of HIV-neutralizing antibodies on invading HIV-1-infected cells is more difficult to predict. Notably, both antibodies MO96 and MO101 were raised from B-lymphocytes obtained from a healthy, uninfected

**Figure 4.** Inhibition of transcytosis of infectious HIV-1 by human anti-HIV-1 env IgM monoclonal antibodies. The in vitro neutralizing Human anti-HIV-1 IgM MO101, MO97, and MO99 and the control non-neutralizing MO6 with or without 5µg/mL rgp160 were added together with HIV-1 SI 6794 infected PBMC during 24h on the apical side to assess inhibition of HIV-1 transmission/transcytosis from the apical side to the basolateral side across the human epithelial cell line Caco-2-plgR+. The inhibition of HIV transcytosis was assessed intracellularly in the cells and in the basolateral supernatant by p24 ELISA. (A) The in vitro neutralizing Human anti-HIV-1 IgM MO101 and the control non-neutralizing MO6 with or without rgp160 (p < 0.01), (B) the in vitro neutralizing anti-HIV-1 IgM MO99 (p < 0.01) and MO97 (p = 0.05) with or without rgp160. Mann Whitney U test was used to determine if the samples were significantly different than the negative control (**p < 0.01 and *p < 0.05). The bars represent the median percent and range inhibited HIV-1 p24 antigen in vitro from two to three repeated experiments. Comparisons of inhibited HIV-1 p24 were performed between control IgM (MO6) and the anti-HIV-1 neutralizing IgM MoAbs.
blood donor, clearly demonstrating that the normal human B-lymphocyte repertoire produce antibodies that are capable of interfering with HIV infection.

Several studies have described the importance of cell-mediated immunity as a primary response to HIV-1 infection. The results of our study suggest a potential important role for nIgM immune mechanisms in the mucosal compartment. It is possible that an epithelium that is sufficiently efficient to allow the transcytosis across epithelial cells of IgM with high to moderate avidity to the HIV-1 envelope and that the pIgR may protect against infection. Several non-specific defence mechanisms such as released lysozomes and antimicrobial peptides such as defensins and innate nitric oxide are present in epithelial cells and at mucosal surfaces. Normally, they protect us from many infections, but when the primary defence barrier fails or a microbiological breakthrough occurs, specific immunity, such as immune memory B-cells secreting sIgA or sIgM are invaluable to the host. Additionally, natural IgM antibodies may also be present in early immune responses as a first line of defence against bacteria and viruses. These antibodies promote the formation of the immune complexes that are required to generate a germination centre in which conventional B-cells can mature and produce high affinity antibodies. It has been postulated that the binding of virus particles with slgM may reduce the viral infectivity intracellularly and may lead to complement activation to facilitate viral clearance by phagocytic cells. It has been shown that sIgM can confer protection by promoting an efficient antiviral IgG response both natural and specific IgM are required for the induction of IgG responses.

The transmission of HIV-1 can occur via exposure of the genital, rectal or mucosa to infected seminal fluid. Some studies have reported that epithelial cells are not capable of being infected, thus allowing the active transport of viruses and immunoglobulins to the submucosa layer, other studies have shown that human colonic epithelial and vaginal epithelial cells can be infected with HIV-1. It has been shown that HIV-1 infection of epithelial cells was neutralized by antisera against three conserved regions and the V3 loop located on the gp120.

We have previously shown that sIgA specific for binding HIV-1 envelope proteins from highly exposed seronegative individuals (HESN) can block HIV-1 transcytosis across the mucosal epithelium. In this study, we have demonstrated that IgM produced from a normal blood donor could be transported across these epithelial cells in concentrations sufficient to prevent the transmission of HIV particles and viral dissemination. We could contemplate the possibility that immediately after HIV entry interactions between nIgM and HIV occur that shape the subsequent immune responses and protect HEPS individuals from infection. Thus, the presence of natural IgM maintains mucosal equilibrium by clearance of apoptotic cells, altered cells by macrophages, dendritic and

**Figure 5.** Inhibition of HIV-1 by human IgM monoclonal antibodies against HIV-1 envelope in human cervical mucosa biopsies and transfer and infection of dendritic cells. Inhibition of HIV-1 actively replicating (RT enzyme activity) from anti-HIV IgM-treated ectocervical biopsy tissue. (A) The quantitative RT activity (pg/ml) in the supernatant at the end of the study period. The bars illustrate the median and range from representative duplicate well inhibition assays. Mann Whitney U test was used to determine if the samples were significantly different than the negative control (**p < 0.01, *p < 0.05). (B). Figure 5B The quantitative RT activity (pg/ml) in the supernatant at the end of the study period. The bars illustrate the median and range from representative duplicate well inhibition assays (**p < 0.01, *p < 0.05).
B-cells and the role in protection against infection was seen in the neutralization, opsonization and recognition of HIV. B-cell isotype class-switching and induction of memory B-cells. However, even though B-1 cells have a special property for self-renewal and there is a continuous IgM production during life, some patients developed a selective loss of natural IgM that leaves them vulnerable to infections. Investigations circumventing the loss of local immunoglobulin immunity have focussed on restoring IgM production via the administration of IL-1858, and the use of monoclonal IgM in experimental autoimmune disease60, but to date these issues have been evaluated only in a few disorders58.

To summarize, our data clearly showed that the specific HIV-1 blocking and neutralizing in vitro properties and these data, together with previous studies16,19,27, support the hypothesis that natural IgM antibodies may be one of several contributing factors in limiting the initial susceptibility to HIV-1 infection via mucosal exposure. If the exposure is at a low infectious dose, even these low concentrations of natural IgM or IgA antibodies may have some preventive effects. Together with other innate factors, such as RANTES, MIP-1/-2 and anti-microbial peptides, they may act as additives or even as synergistic anti-HIV-1 molecules in vivo. We suggest that natural IgM in mucosal epithelial tissues may participate as a potential contributor in the prevention against infection, such as HIV-1. However, the extent of its contribution still need to be better understood and further investigated.

Material and Methods

Human monoclonal antibodies. Human monoclonal antibodies of the IgM isotype specific for the third variable (V3) loop region of the envelope of the HIV-1/LaiIIIB were developed and produced as previously described20,61. Briefly, B-lymphocytes from HIV-1 negative donors were immunized in vitro with recombinant protein pB1, covering amino acid residues 286–467 of the HIV-1/Lai Gp120 (kindly provided by Repligen Corp, Cambridge, MA, USA). After six days of immunization with 25–250 ng pB1/mL, the lymphocytes were immortalized by Epstein-Barr virus infection. Cell lines secreting antigen-specific human IgM MoAbs were detected by antigen-specific ELISA as described previously20,61. In the transcytosis assay, 10-fold concentrated hybridoma supernatants of clones MO96, MO97, MO99 and MO101 specific for HIV-1 V3 and non-HIV binding control IgM clones MO86 and MO6 were used. The Mo86 IgM clone recognizes an epitope outside of the V3 loop and it has been shown not to neutralize infection with HIV-1 and it does not bind HIV-1-infected cells39 and the MO6 IgM clone is directed against digoxin40. All antibodies were developed from blood from HIV-1 seronegative individuals obtained from the University hospital blood bank (Lund, Sweden). Studies were performed with the approval of the ethical review board at The Lund University hospital. All blood was obtained with informed consent according with the Declaration of Helsinki.

Immuoassay (ELISA). Ninety-six well plates (NUNC, Aarhus, Denmark) were coated with 100 ng/well of pB1 (Repligen, Cambridge, MA) or baculovirus recombinant gp160 (Protein Sciences, Meriden, CT, USA) in 100
were obtained from the Karolinska University hospital blood bank (Solna, Sweden). Approval was given by the

tests and Student's t-tests with the Prism GraphPad Software, CA. Human peripheral blood mononuclear cells

to be 400 (range 380–444) mOhm. Statistical analyses were performed with non-parametric Mann-Whitney U

epithelial cells was performed using the Millicell RS resistance apparatus (Millipore, Bedford, MA) and shown

were described below.

were used to measure HIV-1 transcytosis, one T-cell line adapted strain Lai/IIIB28, and two primary HIV-1 iso-

HIV-1 neutralization assay. HIV-1 neutralization in vitro was performed as previously described26. In

Transcytosis of human IgM antibodies. Medium containing human IgM MoAbs (5–9 μg/ml) was added to

Transcytosis of HIV-1 isolates, HIV-1 isolation and HIV-1 blocking. Three different HIV-1 isolates

were used to control the tightness of the epithelial cell barrier. 1.5 mL of recombinant p24 antigen (vector) or gp160 anti-

μl NaCO₃ buffer (pH 9.6). Samples containing MoAbs were diluted in 10 mM sodium phosphate buffer (pH 8.0,

Polarized epithelium cell culture. To measure the transport of the IgM monoclonal antibodies from the

basolateral to the apical side, a polarized epithelial cell line, the human intestinal epithelial cell line Caco-2, trans-

fected with plgR cDNA, was used. Comparison was performed with non-transfected Caco-2 cells, where no IgM

transcytosis was seen (data not shown). Analysis of HIV-1 transcytosis from the apical to the basolateral side was

analysed in the human Caco-2-plgR+ cell line. The cell culture was performed on Transwell nitrocellulose filters

(3-μm pore size filters, Costar, Cambridge, MA, USA) in MEM containing 10% inactivated foetal calf serum

(Gibco, Life Technologies, Scotland) for 8–10 days, until the cell lines formed tight monolayer cultures. One

millilitre of medium/well exchange at the basolateral side and 0.5 mL/well at the apical side was collected and

exchanged every 72 hours. The tightness of the epithelial cell was measured as electrical resistance of >400 Ohms/

Transplantation of human IgM antibodies. Medium containing human IgM MoAbs (5–9 μg/ml) was added

to the basolateral side of the Transwell chamber. Fifty microlitre of medium/chamber side was collected from

the apical side after 0, 1, 2, 4, 6, 12, 48, and 72 hours and analysed by ELISA for the content of IgM. The amounts

of IgM were analysed by capture-ELISA using goat-anti human IgM-specific reagents (Vector, Burlingame, CA,

USA). A standard of purified human IgM was used in the ELISA (Sigma-Aldrich, St. Louis, MO, USA) as a positive

test. Statistical analyses were performed with non-parametric Mann-Whitney U tests and student's t-tests

with the Prism 6 for Mac OS X (GraphPad Software MacKiev, CA, USA).

HIV-1 neutralization assay. HIV-1 neutralization in vitro was performed as previously described26. In

brief, HIV-1 isolates at 25 TCID50/mL concentration was added to serially diluted IgM MoAbs concentrations

(45–0, 1 μg/mL) and control samples in triplicate wells diluted in RPMI 1640 medium with 10% FCS, supple-

mented with 1% penicillin-streptomycin (GIBCO Life Sciences, Paisley, Scotland), in 96 well tissue culture plates

(200 μL/well) and incubated for 1 h at 37°C. Cells were added, 100 000 cells/well in 50 μl/well and incubated 1 h.

Cells were washed twice with 200 ul. RPMI 1640 medium/well by centrifugation and cells were then cultured

for 6 days in complete RPMI 1640-10% FCS medium before HIV-1 p24 quantitative ELISA was performed as

described below.

Transcytosis of HIV-1 isolates, HIV-1 isolation and HIV-1 blocking. Three different HIV-1 isolates

were used to measure HIV-1 transcytosis, one T-cell line adapted strain Lai/IIIB28, and two primary HIV-1 iso-

lates. The two primary HIV-1 clade B isolates represented different phenotypes, the syncytium-inducing (SI)

isolate 6794 and the non-syncytium inducing (NSI) isolate 6727 (Swedish Institute for Infectious Disease Control,

Sweden). The presence of intracellular infectious virus and the inhibitory capacity of the monoclonal antibodies

was measured by using the following procedure: wells containing the Caco-2-plgR+ cells were washed on both

sides three times for 5 min with serum-free medium (37 °C). Phosphate-buffered saline (500 μl) with 1% trypsin

was added to each well, and trypsinization was carried out in Eagle's minimal medium supplemented with 5% FCS.

Cells were spun down and used for HIV-1 virus isolation. HIV cell culture was performed for 2 weeks

with 10° PHA-IL2-activated PBMCs in a mixed lymphocyte culture to measure the presence of viable HIV. The

reduction of >67% of the HIV-1 p24 antigen content in the culture medium compared with the control samples

without antibodies was considered a positive blocking effect.

To control the tightness of the epithelial cell barrier, 1.5 mL of recombinant p24 antigen (vector) or gp160 anti-

gen (1 μL/mL) mixed with medium was added to the apical side and the presence of the recombinant antigens on

the basolateral side was analysed after 1–48 hours (data not shown). This integrity and tightness of the polarized

epithelial cells was performed using the Millicell RS resistance apparatus (Millipore, Bedford, MA) and shown to

be 400 (range 380–444) mOhm. Statistical analyses were performed with non-parametric Mann-Whitney U

tests and Student's t-tests with the Prism GraphPad Software, CA. Human peripheral blood mononuclear cells

were obtained from the Karolinska University hospital blood bank (Solna, Sweden). Approval was given by the
Cervical tissue sampling, monoclonal antibody treatment and virus inoculations. Cervical tissue was obtained from healthy women undergoing prolapse surgery at the Linköping University Hospital (Ethical permit EPN M206-06)\textsuperscript{97}. This collection and study of biopsies was approved by Linköping Ethical Review board and informed consent from all participants was obtained. All methods were carried out with relevant guidelines and regulations at the Linköping University hospital. We confirm that all experimental protocols were approved by the ethical review board of Linköping University hospital.

Cervical samples containing both endo- and/or ectocervical tissues were kept on ice and processed within 30 min after removal. The epithelial layer and lamina propria were separated from the underlying stroma, and explants of approximately 6 mm\(^2\) were placed in culture plates containing RPMI 1640 containing 20 pg/mL Gentamicin, 10 mM HEPES (Fischer Scientific, Gothenburg, Sweden) and 5% pooled HS (Fisher Scientific). Cervical explants were preincubated for 30 min at 37°C for treatment with the different monoclonal antibodies (5 µg/ml) as described for other inhibitors\textsuperscript{66,67}. The tissue explant cultures were infected with HIV-1 primary isolates (0.5 µg p24/ml) and incubated for 2 hours at 37°C and washed four times and transferred to six-well tissue culture plates. After four days, cells were collected, stained for CD3, CD4, CD1a, and p24 and subjected to fluorescence-activated cell sorting (FACS) analysis. To compare results obtained from separate experiments, using cervical explants derived from tissue donors, the HIV infection of emigrating DCs and CD4+ T cells in the absence of monoclonal antibodies was normalized to 100% for each experiment. Infected cell explants were fixed in 4% paraformaldehyde (PFA) and stored for immunohistochemistry and/or immunofluorescence staining. The presence of active HIV-1 virus was analysed with the HIV-1 reverse transcriptase activity ELISA according to the manufacturer's instructions (Caviditech, Uppsala, Sweden).

Statistical analyses. Statistical comparisons were performed using the Graphpad Prism 6, Graphpad InStat (version 6.1a 2015 Software Inc. San Diego, CA, USA). Non-parametrical comparisons between negative control IgM MoAbs and each of the HIV-1 specific IgM specific MoAbs were performed with the Mann Whitney U test. A p-value of <0.05% was considered significant, and ns indicates non-significant.

Data Availability. The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References
1. Gronwall, C., Vas, J. & Silverman, G. J. Protective Roles of Natural IgM Antibodies. Front Immunol 3, 66, https://doi.org/10.3389/fimmu.2012.00066 (2012).
2. Elkon, K. & Casali, P. Nature and functions of autoantibodies. Nat Clin Pract Rheumatol 4, 491–498, https://doi.org/10.1038/ncprheum0895 (2008).
3. Gao, F. et al. Enterovirus 71 viral capsid protein linear epitopes: identification and characterization. Virol J 9, 26, https://doi.org/10.1186/1743-422X-9-26 (2012).
4. Manaresi, E. et al. Differential IgM response to conformational and linear epitopes of parvovirus B19 VP1 and VP2 structural proteins. J Med Virol 64, 67–73 (2001).
5. Mercen, N. M., Galvin, J. E., Adderson, E. E. & Cunningham, M. W. Molecular analysis of cross-reactive anti-myosin/anti-streptococcal mouse monoclonal antibodies. Mol Immunol 37, 901–913 (2000).
6. Burastero, S. E., Casali, P., Wilder, R. L. & Notkins, A. L. Monoreactive high affinity and polyreactive low affinity rheumatoid factors are produced by CD5+ B cells from patients with rheumatoid arthritis. J Exp Med 168, 1979–1992 (1988).
7. Burastero, S. E., Cotolo, M., Desi, V. & Celada, F. Monoreactive and polyreactive rheumatoid factors produced by in vitro Epstein-Barr virus-transformed peripheral blood and synovial B lymphocytes from rheumatoid arthritis patients. Scand J Immunol 32, 347–357 (1990).
8. Fang, Q., Kannapell, C. C., Fu, S. M., Xu, S. & Gaskin, F. VH and VL gene usage by anti-beta-amyloid autoantibodies in Alzheimer’s disease: detection of highly mutated V regions in both heavy and light chains. Clin Immunol Immunopathol 75, 159–167 (1995).
9. Brandtzaeg, P. In Handbook of mucosal immunology (ed. Ogra, P. L. et al.) (Academic Press, San Diego, 1994).
10. Brandtzaeg, P. Presence of IgM in human immunocytes containing various immunoglobulin classes. Nature 252, 418–420 (1974).
11. Brandtzaeg, P. Polymeric IgA is complexed with secretory component (SC) on the surface of human intestinal epithelial cells. Scand J Immunol 8, 39–52 (1978).
12. Shibuya, A. et al. Fc alpha/mu receptor mediates endocytosis of IgM-coated microbes. Nat Immunol 1, 441–446, https://doi.org/10.1038/80886 (2000).
13. Outlaw, M. C. & Dimmock, N. J. Mechanisms of neutralization of influenza virus on mouse tracheal epithelial cells by mouse polymeric monoclonal IgA and polyclonal IgM directed against the viral haemagglutinin. J Gen Virol 71(Pt 1), 69–76, https://doi.org/10.1099/0022-1317-71-1-69 (1990).
14. Crowe, J. The role of antibodies in respiratory viral immunity. Seminars in Virology 7, 273–283 (1996).
15. Mazanec, M. B., Kastel, C. S., Lamm, M. E., Fletcher, D. & Nedrud, J. G. Intracellular neutralization of virus by immunoglobulin A antibodies. Proc Natl Acad Sci USA 89, 6901–6905 (1992).
16. Hocini, H. & Bomsel, M. Infectious human immunodeficiency virus can rapidly penetrate a tight human epithelial barrier by transcytosis in a process impaired by mucosal immunoglobulins. J Infect Dis 179(Suppl 3), S448–453, https://doi.org/10.1086/314802 (1999).
17. Hocini, H. et al. High-level ability of secretory IgA to block HIV type 1 transcytosis: contrasting secretory IgA and IgG responses to glycoprotein 160. AIDS Res Hum Retroviruses 13, 1179–1185, https://doi.org/10.1097/00012-1317-71-1-69 (1997).
18. Devito, C. et al. Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J Immunol 165, 5170–5176 (2000).
19. Chen, W. et al. Cross- Reactive Human IgM-Derived Monoclonal Antibodies that Bind to HIV-1 Envelope Glycoproteins. Viruses 2, 547–565, https://doi.org/10.3390/v20820547 (2010).
20. Ohlin, M. et al. Human MoAbs produced from normal, HIV-1-negative donors and specific for glycoprotein gp120 of the HIV-1 envelope. Clin Exp Immunol 89, 290–295 (1992).
21. Zhou, T. et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445, 732–737, https://doi.org/10.1038/nature05580 (2007).
22. Gorny, M. K. et al. Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein. *Proc Natl Acad Sci USA* **88**, 3238–3242 (1991).

23. Desormeaux, A. et al. The highly conserved layer-3 component of the HIV-1 gp120 inner domain is critical for CD4 required conformational transitions. *J Virol* **87**, 2549–2562, https://doi.org/10.1128/JVI.03104-12 (2013).

24. Herrera, C. et al. Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site. *J Virol* **77**, 1094–1101 (2003).

25. Pantophlet, R. & Burton, D. R. GP120: target for neutralizing HIV-1 antibodies. *Annu Rev Immunol* **24**, 739–769, https://doi.org/10.1146/annurev.immunol.24.021605.090557 (2006).

26. Spearman, P. et al. A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. *J Infect Dis* **203**, 1165–1173, https://doi.org/10.1093/infdis/ijq175 (2011).

27. Planken, S. A. et al. Antibodies to a superantigentic glycoprotein 120 epitope as the basis for developing an HIV vaccine. *J Immunol* **189**, 5367–5381, https://doi.org/10.4049/jimmunol.1200981 (2012).

28. Hansson, L. N., R. In

29. Zirafi, O.

30. Fourie, J. M., Loskutoff, N. & Huyser, C. Semen decontamination for the elimination of seminal HIV-1. *Clin Exp Immunol* **169**, 27–38 (2015).

31. Brandtzaeg, P. Overview of the mucosal immune system. *Curr Top Microbiol Immunol* **146**, 13–25 (1989).

32. Gerhard, W., Mozdzanowska, K., Furchner, M., Washko, G. & Maisee, K. Role of the B-cell response in recovery of mice from primary influenza virus infection. *Immunol Rev* **159**, 93–103 (1997).

33. Rodriguez-Boulan, E. & Nelson, W. J. Morphogenesis of the polarized epithelial cell phenotype. *Science* **245**, 718–725 (1989).

34. Brown, J. S. et al. The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice. *Proc Natl Acad Sci USA* **99**, 16969–16974, https://doi.org/10.1073/pnas.012669199 (2002).

35. Haas, K. M., Poe, J. C., Steeber, D. A. & Tedder, T. F. B1a and B1c cells exhibit distinct developmental requirements and have unique functional roles in innate and adaptive immunity to *S. pneumoniae*. *Immunology* **23**, 7–18, https://doi.org/10.1016/j.jimmunol.2005.04.011 (2005).

36. Alugupalli, K. R. et al. The resolution of relapsing fever borreliosis requires IgM and is concurrent with expansion of B1b lymphocytes. *J Immunol* **170**, 3819–3827 (2003).

37. Alugupalli, K. R. et al. B1b lymphocytes confer T cell-independent long-lasting immunity. *Immunity* **21**, 379–390, https://doi.org/10.1016/j.immuni.2004.06.019 (2004).

38. Choi, Y. S. & Baumgarth, N. Dual role for B-1a cells in immunity to influenza virus infection. *J Exp Med* **205**, 3053–3064, https://doi.org/10.1084/jem.20080979 (2008).

39. Justel, M. et al. IgM levels in plasma predict outcome in severe pandemic influenza. *J Clin Virol* **58**, 564–567, https://doi.org/10.1016/j.jcv.2013.09.006 (2013).

40. Borst, A. et al. Long-lived bone marrow plasma cells are induced early in response to T cell-independent or T cell-dependent antigens. *J Immunol* **168**, 5389–5396, https://doi.org/10.4049/jimmunol.1102808 (2012).

41. Kajihara, M. et al. Inhibition of Marburg virus budding by nonneutralizing antibodies to the envelope glycoprotein. *J Virol* **86**, 13467–13474, https://doi.org/10.1128/JVI.01896-12 (2012).

42. Bomsel, M. et al. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM. *Immunity* **9**, 277–287 (1998).

43. Natvig, J., Johansen, F. E., Nordeng, T. W., Haraldsen, G. & Brandtzaeg, P. Mechanism for enhanced external transfer of dimeric IgA over pentameric IgM: studies of diffusion, binding to the human polymeric Ig receptor, and epithelial transcytosis. *J Immunol* **159**, 4330–4340 (1997).

44. Rowland-Jones, S. L. & McMichael, A. Immune responses in HIV-exposed seronegatives: have they rebelled the virus? *Carr Opin Immunol* **7**, 448–455 (1995).

45. Borrow, P., Lewicki, H., Hahn, B. H., Shaw, G. M. & Oldstone, M. B. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. *J Virol* **68**, 6103–6110 (1994).

46. Fang, F. C. Perspectives series: host/pathogen interactions. *Mechanisms of nitric oxide-related antimicrobial activity*. *J Clin Invest* **99**, 2818–2825, https://doi.org/10.1172/JCI14973 (1997).

47. Diamond, G., Legarda, D. & Ryan, L. K. The innate immune response of the respiratory epithelium. *Immunol Rev* **173**, 27–38 (2000).

48. Hansson, L. N., R. In *Immunology* **2** (ed. L; Wiggell Hansson, H) 245–258 (Esselte, 1998).

49. Frankowski, M. et al. The higher frequency of IgA deficiency among Swedish twins is not explained by HLA haplotypes. *Genes Immun* **16**, 199–205, https://doi.org/10.1038/genetics.2014.78 (2015).

50. Baumgarth, N. et al. B-1 and B-2 cell-derived immunoglobulin M antibodies are nonredundant components of the protective response to influenza virus infection. *J Exp Med* **192**, 271–280 (2000).

51. Ochsnebin, A. F. et al. Control of early viral and bacterial distribution and disease by natural antibodies. *Science* **286**, 2156–2159 (1999).

52. Kinoshita, M. et al. Restoration of natural IgM production from liver B cells by exogenous IL-18 improves the survival of burn-injured mice infected with Pseudomonas aeruginosa. *J Immunol* **177**, 4627–4635 (2006).

53. Vogt, M. W. et al. Isolation of HTLV-III/LAV from cervical secretions of women at risk for AIDS. *JAMA* **255**, 3995–3999 (1988).

54. Wang, J. S. et al. The role of complement and complement receptors in induction and regulation of immunity. *Annu Rev Immunol* **16**, 545–568, https://doi.org/10.1146/annurev.immunol.16.1.545 (1998).

55. Boulhão, H. & Kaveri, S. Multi-faceted role of naturally occurring autoantibodies in fighting pathogens. *Adv Exp Med Biol* **750**, 100–113, https://doi.org/10.1007/978-1-4614-3461-0_8 (2012).

56. Winkelstein, W. Jr et al. Sexual practices and risk of infection by the human immunodeficiency virus. The San Francisco Men’s Health Study. *JAMA* **257**, 321–325 (1987).

57. Harrington, A. E. et al. Human monomolecular antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. *Proc Natl Acad Sci USA* **97**, 6820–6825 (2000).

58. Borregaard, C. A., Danielsen, L. M. & Deitcher, D. L. Human monoclonal antibodies produced by primary in vitro immunization of peripheral blood lymphocytes. *Proc Natl Acad Sci USA* **85**, 3995–3999 (1988).

59. Danielsen, L. et al. Human monoclonal antibodies with different fine specificity for digoxin derivatives: cloning of heavy and light chain variable region sequences. *Immunity* **7**, 50–54 (1991).

60. Mostov, K. E. & Deitcher, D. L. Polymeric immunoglobulin receptor expressed in MDCK cells transcytoses IgA. *Cell* **46**, 613–621 (1986).
64. Sundqvist, V. A. et al. Human immunodeficiency virus type 1 p24 production and antigenic variation in tissue culture of isolates with various growth characteristics. *J Med Virol* **29**, 170–175 (1989).

65. Devito, C., Levi, M., Broliden, K. & Hinkula, J. Mapping of B-cell epitopes in rabbits immunised with various gag antigens for the production of HIV-1 gag capture ELISA reagents. *J Immunol Methods* **238**, 69–80 (2000).

66. Tjomsland, V. et al. Complement opsonization of HIV-1 enhances the uptake by dendritic cells and involves the endocytic lectin and integrin receptor families. *PloS One* **6**, e23542, https://doi.org/10.1371/journal.pone.0023542 (2011).

67. Tjomsland, V. et al. Blocking of integrins inhibits HIV-1 infection of human cervical mucosa immune cells with free and complement-opsonized virions. *Eur J Immunol* **43**, 2361–2372, https://doi.org/10.1002/eji.201243257 (2013).

**Acknowledgements**
We gratefully acknowledge Prof. Jean-Pierre Kraehenbuhl (ISREC, Lausanne, Switzerland) for providing the Caco-2-pIgR+ cell line. This work was financially supported by the Swedish Medical Research Fund and the MIIC support Fund at Linköping University.

**Author Contributions**
C.D.: Experimental work, writing and experimental design
R.E.: Experimental work, graphic design of figures,
T.F.: Experimental work, L.S.: Experimental planning, Reagent supply and contribution, Mats Ohlin; Writing, reagent supply, M.L.: Experimental design, Writing, Editing, K.B.: Experimental design, Writing J.H.: Technical, experimental work, experimental design, writing contribution.

**Additional Information**

**Competing Interests:** The authors declare no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2018

---

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.